Immunoglobulin G1 [188,412-bis[4-(azidomethyl)-L-phenylalanine]], anti-(human folate receptor ?) (human-Mus musculus monoclonal SP8166 ?1-chain), disulfide with human-Mus musculus monoclonal SP8166 ?-chain, dimer, click reaction product with 3-[[[[4-[[N-[4-(11,12-didehydrodibenz[b,f]azocin-5(6H)-yl)-1,4-dioxobutyl]-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]amino]-N,?,?-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-buten-1-yl]-N,3-dimethyl-L-valinamide (1:4)
Fallopian Tube Cancer
Sutro Biopharma, Inc.antibody_drug_conjugatePhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 31/ 100
- Competitive Position
- 65/ 100
Competitive context
124 Active assets in the Fallopian Tube Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Mirvetuximab Soravtansine AbbVie | Phase 3 | BB |
Inno-206 Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 | BB |
Irinotecan Tianjin Medical University Cancer Institute and Hospital | Phase 3 | BB |
Carboplatin Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 3 | BB |
Hycamtin Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Immunoglobulin G1 [188,412-bis[4-(azidomethyl)-L-phenylalanine]], anti-(human folate receptor ?) (human-Mus musculus monoclonal SP8166 ?1-chain), disulfide with human-Mus musculus monoclonal SP8166 ?-chain, dimer, click reaction product with 3-[[[[4-[[N-[4-(11,12-didehydrodibenz[b,f]azocin-5(6H)-yl)-1,4-dioxobutyl]-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]amino]-N,?,?-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-buten-1-yl]-N,3-dimethyl-L-valinamide (1:4) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →